Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 39,880

Document Document Title
WO/2018/218696A1
Provided is a ligand compound ofα7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nico...  
WO/2018/220253A1
The present invention relates to novel carboxylic acid derivatives of 11-oxo-11H-pyrido [2,1-b]quinazoline-6-carboxamide as potent inhibitors of protein kinase, to pharmaceutical compositions containing them and to the use of said compou...  
WO/2018/218963A1
Provided in the present invention are a pharmaceutically acceptable salt of an epidermal growth factor receptor (EGFR) inhibitor, a crystal form thereof, a preparation method therefor and an application thereof. The structural formula of...  
WO/2018/221551A1
Provided is a Lewy body disease therapeutic agent that contains (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofura n-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one, which is represented by formula (I), or a pharmaceutically accepta...  
WO/2018/219356A1
The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formu...  
WO/2018/220252A1
The present invention relates to novel 11-oxo-11H-pyrido[2,1 b]quinazoline-6-carboxamide derivatives of formula (I) as potent inhibitors of protein kinase, to pharmaceutical compositions containing them and to the use of said compounds f...  
WO/2018/219772A1
Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human ΡΒΚδ isoform, are accordingly of benefit in medicine, for exampl...  
WO/2018/214846A1
Provided is an imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong ...  
WO/2018/216913A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/218100A1
The present disclosure relates to solid forms of N-{[2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihyd ro-1'H-spiro[cyclopropane-1,4'-[2,7]naphthyridin]-6'-yl]meth yl}acrylamide, methods of preparation thereof, and intermediates i...  
WO/2018/214961A1
The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceuti...  
WO/2018/215304A1
Compounds of formula I wherein X is S, SO or SO2; X1 is O, S or NR3; R3 is C1-C4 alkyl; R1 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl or C3-C6 cycloalkyl, C1-C4 alkyl; R2 is halogen, C1-C6 haloalkyl, C1-C4 haloalkylsulfanyl, C1-C4...  
WO/2018/217651A1
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.  
WO/2018/215318A1
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.  
WO/2018/218038A1
The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNKl, MNK2, or both are inhibited in the genet...  
WO/2018/214875A1
Disclosed in the present invention is a new 11-oxo-7,11-dihydro-6h-benzo-[f]pyrido[1,2-d][1,4]azepine oxepin-10-carboxylic acid derivative serving as a hepatitis B virus surface antigen inhibitor. Specifically disclosed are a compound re...  
WO/2018/214222A1
Provided are a particular compound of 1-pyridine-6-methoxy-9-(3-methylbenzyl)β-carboline and a synthetic method and application thereof. The compound has significant anti-renal fibrosis activity in vitro and can be used in preparing a d...  
WO/2018/214754A1
Provided are a triazole derivative and the use thereof in agriculture. Specifically, provided are a compound as shown in formula (I) or a stereoisomer, an oxynitride and a salt of the compound shown in formula (I), and a preparation meth...  
WO/2018/215557A1
The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially...  
WO/2018/215316A1
The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine ...  
WO/2018/217766A1
Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome ...  
WO/2018/211275A1
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor ...  
WO/2018/213211A1
The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present d...  
WO/2018/213422A1
The present invention features compounds useful in the treatment of BAF complex related disorders.  
WO/2018/210659A1
Heteroaryl compounds as agrochemical fungicides Formula (I) The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form...  
WO/2018/213219A1
Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds having the structures below (I) are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). ...  
WO/2018/212534A1
The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceuti...  
WO/2018/210238A1
The present application provides an application of a fused acridine derivative shown in formula (I) or a pharmaceutically acceptable acid salt or solvate thereof in anti-inflammation. The definition of each substituent in formula (I) can...  
WO/2018/210661A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S- oxide, a prodrug or mixture thereof. The p...  
WO/2018/209445A1
There is described compounds, compositions, methods, and uses, of treating a subject having, suspected or having, or at risk of having, a prion disease, comprising: administering a cholesterol 24-hydroxylase (CH24OH)-activating compound.  
WO/2018/213810A1
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject...  
WO/2018/213769A1
A deuterated compound having structural formula I or a pharmaceutically acceptable salt thereof: Values and example values of the variable in formula (I) are disclosed herein. Also disclosed are the use of compounds of formula (I) in the...  
WO/2018/211324A1
Described herein are prodrugs of heterocyclic compounds, compositions, and methods for their use for the treatment of disease.  
WO/2018/211323A1
Described herein are heterocyclic compounds, compositions, and methods for their use for treatment of disease.  
WO/2018/211148A1
The present invention relates to bisquinolinium derivatives of formula (I): (I) With Y1, Y2, Z1, Z2, X 2- and L as defined in the claims, useful for treating or preventing cancers associated with the Epstein-Barr Virus (EBV-related cance...  
WO/2018/210314A1
The present invention relates to the field of pharmaceutical chemistry, and provides a five- and six-membered aza-aromatic compound, a preparation method therefor, a pharmaceutical composition, and an application. Specifically, the prese...  
WO/2018/211530A1
The present invention relates to substituted methanopyrido [2,1-a]isoindolones of formula I, wherein, R1 is selected from phenylsulfonyl or p-toluenesulfonyl; andn = 1, 2, 3; their derivatives, stereoisomers, pharmaceutically acceptable ...  
WO/2018/210660A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S-oxide, a prodrug or mixture thereof. The pr...  
WO/2018/210658A1
The present invention relates to heteroaryl compounds of formula (I) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer, an isotopic form, a N-oxide, a S-oxide, a prodrug or mixture thereof. The pr...  
WO/2018/206547A1
The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of Bub1 kinase, and component B being an ATR inhibitor. Another aspect of the present invention relates...  
WO/2018/205916A1
The present invention falls within the field of medical chemistry, and in particular relates to an FGFR4 inhibitor as shown in formula II, a preparation method thereof, a pharmaceutical composition comprising the inhibitor, and the use o...  
WO/2018/205299A1
Disclosed are a 4,5-disubstituted-1-hydro-pyrrole(2,3-f)quinolone-2,7,9-tric arboxylate compound, an analogue of same or a derivative of same, the structure thereof is as represented by formula I: where R1 and R4 respectively are indepen...  
WO/2018/207882A1
Provided are compounds that can have an inhibitory action on BET family proteins and are expected to be useful as agents for the prevention or treatment of, for example, autoimmune diseases and/or inflammatory diseases (for example, rheu...  
WO/2018/208595A1
Disclosed are compounds of Formula 1, including ail geometric and stereoisomers, N-oxides, and salts thereof, wherein A, X, Y, Z, R1, R2a, R2b and Q are as defined in the disclosure. Also disclosed are compositions containing the compoun...  
WO/2018/209049A1
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...  
WO/2018/208557A1
3-(((((2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan -6-yl) oxy)sulfonyl)oxy)-2,2-dimethylpropanoate derivatives and related compounds as perorally administered prodrugs of beta-lactamase inhibitors for treating bacterial infecti...  
WO/2018/205928A1
The present invention relates to indolizine derivatives and applications thereof in medicine. In particular, disclosed in the present invention are novel substituted indolizine derivatives of formula I, or isotopically-labeled compounds ...  
WO/2018/208769A1
Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compoun...  
WO/2018/204236A1
The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-te trahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phen ol. The invention also pr...  

Matches 1 - 50 out of 39,880